The allowance of this patent comes shortly after one of Lipoxen’s cornerstone ImuXen patents, which covers the encapsulation of DNA inside a liposome, was allowed in the US. Both these approaches further protect Lipoxen’s position in the field of DNA vaccine delivery technology and help ensure that its advanced ImuXen technology continues to be at the forefront of novel vaccine development.
The capisome technology has the potential to be used in gene therapy and other nucleic acid-based therapies such as siRNA. Other benefits are expected to include low toxicity and capability to carry large amounts of DNA. The technology can also be applied in conjunction with Lipoxen’s current ImuXen co-delivery approach, in which DNA vaccines and the proteins they encode are delivered together in order to provide an enhanced immune response.
Scott Maguire, CEO of Lipoxen, said: “The potential widespread use of the capisome technology beyond vaccines into delivery of other DNA-based medicines increases the value of our patent estate, and we expect it to play a key role in the generation of further deals and R&D collaborations.”